Global Aminoglycoside Market is expected to reach USD 1.68 billion by 2022
growing at an estimated CAGR of 3.5% from 2015 to 2022, according to a new
report by Grand View Research, Inc. This expected growth in demand can be
ascribed to the increasing incidences of animal disease outbreaks leading to
high utilization of antibiotics.
However, reduction in
prescription rate of aminoglycoside antibiotics due to side effects associated
with usage of these drugs that include severe ototoxicity, nephrotoxicity, and
neuromuscular blockade are expected to affect the market growth negatively.
Furthermore, regulatory disapproval for the usage of certain aminoglycoside in
regions is also anticipated to attribute for subordinate growth in this
industry.
Further key findings from the report suggest:
- Neomycin and tobramycin together contributed
for over USD 600 million as revenue in this market owing to higher usage
and prescription of these drugs for treatment of different bacterial
infections. Neomycin finds higher usage in topical formulations for
treatment of different skin infections.
- Injectables accounted for the largest share of
revenue amongst other routes of administration owing to higher usage for
treatment of tuberculosis, MDR-TB, and XDR-TB. Use of second line anti
tuberculosis drugs such as kanamycin & capreomycin by global organizations
is attributive for generation of maximum revenue in this segment.
- Human use for treatment of respiratory
disorders accounted for largest share in applications segment owing to
rise in global incidence of tuberculosis. Furthermore, other bacterial
infections of respiratory tract that can be treated using aminoglycoside
class of antibiotics are anticipated to contribute for expected growth in
this segment.
- Veterinary treatment is expected to boost
industrial growth in the coming years owing to higher incidence of animal
diseases outbreaks. However, these drugs have restrictive regulations for
administration to food-producing animals as it may lead to toxic effects
and resistance development on humans after consumption of animal
originated food.
- Asia Pacific was the largest market, accounting
for over 40% of revenue in aminoglycoside industry owing to, the presence
of market players in this region coupled with higher rate of tuberculosis
incidences herein.
- South Africa spearheaded growth in the MEA market.
The presence of relatively higher demand and consumption of injectable
solutions in this region because of increase in incidence rate of MDR-TB
and other drug resistant infections are some regional growth drivers.
- Key participants of the aminoglycoside market
include Vega Pharma Ltd., Kremoint Pharma Pvt. Ltd, Xian Wison Biological
Technology Co., Ltd., Jiangxi Bolai Pharmacy Co., Ltd., Medson
Pharmaceuticals, Hangzhou Uniwise International Co., Ltd., Yi Chang
Veterinary Medicine Factory, HuvePharma, and Medico Remedies Pvt. Ltd.
- Market players are involved in the development
of products with newer formulations and lesser side effects in order to
treat eradicate bacterial infections that are resistant to other class of
antibiotics.
No comments:
Post a Comment